Biomedical treatment refers to the branch of treatment that assists individuals diagnosed with psychological disorders with the help of prescription medication. According to Lisa Hartling (2012) in her article titled Antipsychotics in Adults with Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications, there are 20 commercial first generation antipsychotics (FGA) and second generation antipsychotics (SGA) that have been approved by the Food and Drug Administration (FDA) (Lisa Hartling, 2012, p. 498). The research that was provided by Lisa Hartling compares the effectiveness, harm, and benefits that FGA and SGA provides to individuals diagnosed with schizophrenia. Ms. Hartling has found that over three-quarters of individuals diagnosed with schizophrenia have been prescribed SGA over FGA, which includes
…show more content…
In table 2 of Ms. Hartling’s research, rates of hospitalization/rehospitalization were significantly higher in the FGAs Haloperidol and Perphenazine versus the SGAs tested, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone (Lisa Hartling, 2012, p. 502). FGAs have recently been found to help with depression or bipolar disorder instead of psychosis/ schizophrenia, even though FGAs were originally created for the treatment of psychosis/ schizophrenia. Lisa Hartling states in her discussion, “At this time, evidence supporting the use of SGAs for negative symptoms is stronger than that supporting their use for positive symptoms; olanzapine ad risperidone were found to be more efficacious than haloperidol in reducing such symptoms as blunted affect and withdrawal” (Lisa Hartling, 2012, p. 506). However with the help of these antipsychotics relieving symptoms of schizophrenia, there was on detriment that occurred to Ms. Hartling and her research team. They found that with the use of SGA olanzapine there was a low-evidence risk of the possibility of developing a metabolic syndrome while taking this
In table 2 of Ms. Hartling’s research, rates of hospitalization/rehospitalization were significantly higher in the FGAs Haloperidol and Perphenazine versus the SGAs tested, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone (Lisa Hartling, 2012, p. 502). FGAs have recently been found to help with depression or bipolar disorder instead of psychosis/ schizophrenia, even though FGAs were originally created for the treatment of psychosis/ schizophrenia. Lisa Hartling states in her discussion, “At this time, evidence supporting the use of SGAs for negative symptoms is stronger than that supporting their use for positive symptoms; olanzapine ad risperidone were found to be more efficacious than haloperidol in reducing such symptoms as blunted affect and withdrawal” (Lisa Hartling, 2012, p. 506). However with the help of these antipsychotics relieving symptoms of schizophrenia, there was on detriment that occurred to Ms. Hartling and her research team. They found that with the use of SGA olanzapine there was a low-evidence risk of the possibility of developing a metabolic syndrome while taking this